Key takeaways
- GLP-1 medications like Ozempic can cause dry mouth, which is a secondary driver of tooth decay and gum disease.
What happened
In an August 2026 interview on the CBS6 Morning Show, Dr. David Kavanagh of Columbia Family Dentistry highlighted an emerging oral health risk for patients taking GLP-1 medications like Ozempic and Wegovy. Dr. Kavanagh warned that these popular weight-loss drugs can trigger a significant drop in salivary flow, leading to chronic dry mouth (xerostomia). This lack of saliva lowers the mouth's pH level, creating an acidic environment that can rapidly accelerate tooth decay, gum disease, and bad breath.
Why it matters
While millions of Americans focus on the systemic benefits of GLP-1 therapies, under-reported side effects like severe dry mouth can compromise long-term dental health. Saliva acts as a natural buffer that neutralizes dietary acids and washes away food particles. When salivary flow is diminished, the protective barrier is lost, making teeth highly vulnerable to enamel erosion and cavities.
For the growing number of patients purchasing GLP-1s through online telehealth platforms, this highlights the necessity of comprehensive medical intake forms and ongoing communication with physical healthcare providers. Patients must actively manage these secondary side effects rather than stopping their essential therapies.
What the data says
According to Dr. Kavanagh, the dental issues colloquially dubbed "Ozempic mouth" or "Ozempic teeth" on social media are not caused by direct chemical damage from the medication itself. Instead, the deterioration of oral health is a secondary complication of decreased salivary flow.
When saliva production drops, the oral pH level falls below the neutral zone. This acidic environment allows bacteria to flourish, leading to:
- Increased rates of dental caries (cavities)
- Accelerated gum inflammation and periodontal disease
- Chronic halitosis (bad breath)
Dr. Kavanagh noted that dry mouth is a common side effect of many prescription medications, but the massive scale of GLP-1 adoption has brought this specific risk to the forefront. To combat this, he advises patients to maintain rigorous oral hygiene, brush twice daily, use a fluoride toothpaste, and limit the consumption of highly acidic foods and beverages.
How it compares
Traditional weight-loss methods, such as bariatric surgery, carry their own oral health risks, often related to nutritional deficiencies or acid reflux. However, GLP-1 medications introduce a distinct daily challenge of chronic dry mouth.
Unlike brand-name GLP-1 medications like Wegovy and Zepbound, which can retail for upward of $1,000 to $1,350 per month without insurance, compounded semaglutide and tirzepatide offered through online providers typically cost between $200 and $400 monthly.
Regardless of whether a patient uses brand-name injections, oral formulations, or compounded alternatives, the physiological side effect of dry mouth remains a risk. This makes it vital for telehealth buyers to compare options on our compare page to find programs that offer comprehensive clinical support, rather than just writing prescriptions.
How this fits the bigger picture
This dental warning highlights a broader trend: as GLP-1 usage expands to a massive segment of the US population, secondary and lifestyle side effects are coming to light. Our prior coverage has tracked how these medications are shifting consumer habits, such as in our article detailing how GLP-1 users cut ice cream consumption by 10%.
As patients modify what they eat, the combination of dietary changes and reduced salivary buffer capacity makes dental monitoring even more critical. Furthermore, as discussed in our report on how one in five adults have tried a GLP-1, the sheer volume of patients obtaining these medications through digital clinics means that traditional dentist-patient relationships must adapt.
Dentists are increasingly acting as crucial triage points, identifying systemic medication side effects that patients might not think to report to their online prescribing doctors.
What happens next
As dental professionals continue to raise awareness about GLP-1-induced xerostomia, clinical guidelines for managing "Ozempic mouth" are expected to become more standardized. Patients currently taking these medications should schedule regular dental cleanings and inform their dentists about their GLP-1 regimens.
In the meantime, researchers continue to study the long-term impact of GLP-1 therapies on overall systemic health, reinforcing the dentist's role as an essential partner in a patient's multidisciplinary care team.
CompareRx does not provide medical advice. Always consult with your doctor or dentist before starting or altering any medication regimen.